Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
A phase 2 trial of the actinium-225 antibody rosopatamab tetraxetan (with an indium-111 version for dosimetry) in prostate cancer, run by Convergent Therapeutics, now recruiting.
Overview
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) is a phase 2 interventional study registered as NCT06549465 by Convergent Therapeutics, with 93 participants planned, started 2024-08-06 and due to reach its primary completion in August 2027 (estimated; moved from 20 April 2027 in the registry update of 2 October 2026). Interventions recorded: In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan, Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan and Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- AgentAAA817
Shares Actinium-225, Prostate cancer and the tag pipeline.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares Prostate cancer and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares Prostate cancer and the tag pipeline.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares Prostate cancer and the tag pipeline.
- TrialTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Shares Actinium-225 and the tag pipeline.